Shire has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for a new, alternate formulation of Vyvanse (lisdexamfetamine dimesylate), a drug to treat attention deficit/hyperactivity disorder, as a chewable tablet for patients who may have difficulty swallowing or opening a capsule. Vyvanse capsules can be swallowed whole or consumed by opening and mixing the entire contents into water, orange juice or yogurt.

In the US, Vyvanse capsules are indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ages six and above and for the treatment of moderate to severe binge eating disorder in adults.

Source: Shire